← Eichor
Study identifier: NCT05883371 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

IMPACT - AndHealth Autoimmune Research Registry

Condition: Arthritis, Rheumatoid · Arthritis, Psoriatic · Psoriasis  ·  Sponsor: AndHealth

PhaseN/A
Planned participants2500
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This is a patient research registry aimed at evaluating the effectiveness of a comprehensive, root-cause medical approach ("AndHealth program") for autoimmune disorders. This approach involves a combination of pharmacological and non-pharmacological therapies offered under the care of a licensed physician with the support of health coaches. While protocol guidance is provided, the therapeutic approach is personalized to the individual needs of patients. The autoimmune disorders of focus in this registry include rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis. A variety of validated labs, patient-reported outcomes, and medication usage will be assessed among participating patients over a period of up to five years to evaluate the long-term effectiveness of this approach.

This description comes directly from the study's public registry record.

Talk to the study team

Sonja Horner  ·  614-697-3296  ·  shorner@andhealth.com

Always discuss trial participation with your own doctor first.

Locations (1)

AndHealthColumbus, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05883371